Erste Group Bank Has Pessimistic View of LLY FY2026 Earnings

Key Points

• Erste Group Bank cut its FY2026 EPS forecast for Eli Lilly to $34.93 from $35.34, below the analyst consensus of $36.77 and Lilly’s guidance range of $35.50–$36.50.
• Lilly’s latest quarter significantly exceeded expectations, with EPS of $8.38 versus $6.40 expected and revenue of $22.97 billion, up 47.7% year over year.
• Despite the cautious estimate, analysts remain broadly bullish: Lilly has a “Moderate Buy” consensus rating and an average price target of $1,292.18, while its obesity-drug portfolio continues to support growth expectations.

Eli Lilly and Company (NYSE:LLY - Free Report) - Erste Group Bank dropped their FY2026 earnings per share estimates for Eli Lilly and Company in a research report issued to clients and investors on Wednesday, August 5th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $34.93 per share for the year, down from their previous estimate of $35.34. The consensus estimate for Eli Lilly and Company's current full-year earnings is $36.77 per share.

Several other equities research analysts have also issued reports on LLY. BMO Capital Markets restated an "outperform" rating and set a $1,400.00 price target on shares of Eli Lilly and Company in a research note on Thursday. Leerink Partners boosted their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an "outperform" rating in a research note on Thursday, June 25th. Truist Financial upped their price target on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a research report on Friday. Bank of America lifted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a report on Friday, July 10th. Finally, Royal Bank Of Canada upped their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an "outperform" rating in a report on Wednesday, July 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,292.18.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,230.00 on Tuesday. The company has a market capitalization of $1.16 trillion, a PE ratio of 41.28, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 52-week low of $625.90 and a 52-week high of $1,249.45. The company has a 50-day simple moving average of $1,162.38 and a 200 day simple moving average of $1,048.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business's revenue was up 47.7% compared to the same quarter last year. During the same period last year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company's payout ratio is 23.22%.

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company's stock.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors have recently modified their holdings of the company. Jupiter Wealth Management LLC grew its position in Eli Lilly and Company by 20.0% during the second quarter. Jupiter Wealth Management LLC now owns 2,084 shares of the company's stock valued at $2,500,000 after acquiring an additional 348 shares during the last quarter. Glaxis Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $5,613,000. Vise Technologies Inc. boosted its stake in shares of Eli Lilly and Company by 45.8% in the 2nd quarter. Vise Technologies Inc. now owns 34,353 shares of the company's stock valued at $41,204,000 after purchasing an additional 10,795 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd grew its holdings in shares of Eli Lilly and Company by 21.9% during the 2nd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 17,672 shares of the company's stock valued at $21,196,000 after purchasing an additional 3,176 shares during the last quarter. Finally, E Fund Management Co. Ltd. raised its position in Eli Lilly and Company by 7.1% in the 2nd quarter. E Fund Management Co. Ltd. now owns 9,177 shares of the company's stock worth $11,007,000 after purchasing an additional 605 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. This is the pill’s first approval outside the United States and opens access to a large European market. Foundayo will initially be sold privately by prescription; potential National Health Service coverage depends on a cost-effectiveness review. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: The authorization strengthens Lilly’s competitive position against Novo Nordisk in the fast-growing obesity-treatment market. Investors are evaluating whether a convenient oral GLP-1 option can broaden patient adoption beyond injectable therapies. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Analysts raised Lilly’s estimated fair value to $1,297.31 from $1,270.37, citing momentum in Mounjaro, Zepbound, retatrutide and Foundayo. The revisions reinforce expectations for continued GLP-1-driven growth. Eli Lilly Fair Value Bump
• Positive Sentiment: Lilly’s latest quarter delivered revenue of approximately $22.97 billion, up 47.7% year over year, and EPS of $8.38 versus the $6.40 consensus estimate. Fiscal 2026 EPS guidance of $35.50 to $36.50 signals management’s confidence in demand. Eli Lilly Posts Blowout Growth
• Neutral Sentiment: Possible U.S. policies encouraging domestic drug manufacturing could benefit Lilly if its production footprint is viewed favorably, but compliance costs and final policy requirements remain uncertain. Lilly and Novo Nordisk Manufacturing Policies
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares for about $5.95 million, reducing her holdings by 29.63%. Because the transaction was made under a pre-arranged Rule 10b5-1 plan, it is a limited signal regarding Lilly’s business outlook. SEC Form 4 Filing

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source